Dermatology News

Dermatology

sponsor

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Patel RV et al. - Many of the therapies for moderate to severe psoriasis, including PUVA, traditional systemic therapies, and some biologic therapies, may increase the risk of malignancy. Appropriate patient counseling and selection, as well as clinical follow-up, are necessary to maximize safety with these agents.

 

Related Articles

Pediatric psoriasis: an update
Therapeutics and Clinical Risk Management, 10/22/09    Relevance Score: 95%

FDA Approves New Drug to Treat Psoriasis
Internet Source, 11/02/09    Relevance Score: 91%

Study shows major burden of psoriasis
Internet Source, 10/29/09    Relevance Score: 91%

Prevalence of myocardial infarction in patients with psoriasis in central China
Journal of the European Academy of Dermatology and Venereology, 10/27/09    Relevance Score: 91%

Why nail psoriasis remains difficult to treat
Dermatology in Practice, 10/12/09    Relevance Score: 91%

Today in Dermatologic Oncology...keeping you current

Outcomes of Childhood Hemangiomas Treated with the Pulsed-Dye Laser with Dynamic Cooling: A Retrospective Chart Analysis
Dermatologic Surgery, 12/16/09

Expression of Ca2+-Activated K+ Channels in Human Dermal Fibroblasts and Their Roles in Apoptosis
Skin Pharmacology and Applied Skin Physiology, 12/16/09

Beclin 1 and LC3 autophagic gene expression in cutaneous melanocytic lesions
Human Pathology, 12/16/09